Current Opinion in Pulmonary Medicine 2017 April [Epub ahead of print] [Link] Arnold DT, Clive AO Abstract PURPOSE OF REVIEW: Malignant pleural mesothelioma is an aggressive malignancy with a very poor prognosis. The majority of patients require pleural procedures for diagnostic or fluid management purposes. Damage to the pleura during these procedures can lead to […]
Category Archives: Pleural
Three-dimensional finite-element based deformable image registration for evaluation of pleural cavity irradiation during photodynamic therapy
Medical Physics 2017 April [Epub ahead of print] [Link] Penjweini R, Kim MM, Zhu TC Abstract PURPOSE: Photodynamic therapy (PDT) is used after surgical resection to treat the microscopic disease for malignant pleural mesothelioma and to increase survival rates. As accurate light delivery is imperative to PDT efficacy, the deformation of the pleural volume during […]
Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma
Oncotarget 2017 March [Epub ahead of print] [Link] Mairinger FD, Vollbrecht C, Flom E, Christoph DC, Schmid KW, Kollmeier J, Popper HH, Mairinger T, Walter RFH Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare tumor linked to a dismal prognosis. Even the most effective chemotherapeutical regime of pemetrexed combined with cisplatin leads to a […]
CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.
Respiratory Research 2017 April [Link] Cortes-Dericks L, Schmid RA Abstract Malignant pleural mesothelioma (MPM) is a rare and highly drug resistant tumor arising from the mesothelial surfaces of the lung pleura. The standard method to confirm MPM is the tedious, time-consuming cytological examination of cancer biopsy. Biomarkers that are detectable in pleural effusion or patient […]
Malignant pleural mesothelioma: single-institution experience of 101 patients over a 15-year period.
Acta Chirugica Belgica 2017 June [Link] Domen A, De Laet C, Vanderbruggen W, Gielis J, Hendriks JM, Lauwers P, Janssens A, Hiddinga B, Van Meerbeeck JP, Van Schil PE Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare but aggressive neoplasm that typically originates from the mesothelial surfaces of the pleural cavity. Exposure to asbestos […]
A novel BRCA1-associated protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair.
Journal of Thoracic Oncology 2017 April [Epub ahead of print] [Link] Parrotta R, Okonska A, Ronner M, Weder W, Stahel R, Penengo L, Felley-Bosco E Abstract INTRODUCTION: BRCA1-associated protein-1, BAP1, is a tumor suppressor involved in multiple cellular processes such as transcriptional regulation, chromatin modification by deubiquitinating histone 2A and DNA repair. BAP1 mutations are […]
Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.
Journal of Clinical Oncology 2017 April [Epub ahead of print] [Link] Beddowes E, Spicer J, Chan PY, Khadeir R, Corbacho JG, Repana D, Steele JP, Schmid P, Szyszko T, Cook G, Diaz M, Feng X, Johnston A, Thomson J, Sheaff M, Wu BW, Bomalaski J, Pacey S, Szlosarek PW Abstract Purpose Pegylated arginine deiminase (ADI-PEG […]
April 19, 2017
Biphasic or Mixed, Chemotherapy, Cisplatin (Platinol ®), Full Archive, Lung Cancer, Pemetrexed (Alimta), Pleural, RECIST, Sarcomatoid
Comments Off on Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.
Disease Markers 2017 [Epub March 2017] [Link] Ying S, Jiang Z, He X, Yu M, Chen R, Chen J, Ru G, Chen Y, Chen W, Zhu L, Li T, Zhang Y1, Guo X, Yin X, Zhang X, Lou J Abstract High-mobility group box 1 (HMGB1) functions as a proinflammatory cytokine and is one of the […]
Histopathologic features predict survival in diffuse pleural malignant mesothelioma on pleural biopsies
International Journal of Pathology 2017 March 27 [Epub ahead of print] [Link] Habougit C, Trombert-Paviot B, Karpathiou G, Casteillo F, Bayle-Bleuez S, Fournel P, Vergnon JM, Tiffet O, Péoc’h M, Forest F Abstract Malignant pleural mesothelioma is a rare tumor with a poor prognosis. The only universally recognized pathological prognostic factor is histopathological subtype with […]
Intensity modulated radiation therapy after extra-pleural pneumonectomy for malignant pleural mesothelioma is feasible without fatal pulmonary toxicity and provides good survival.
Asia-Pacific Journal of Clinical Oncology 2017 March 29 [Epub ahead of print] [